-
1
Primary aldosteronism (PA) occurs in 5% to 15% of hypertensive patients, with higher rates in those with resistant hypertension.
-
2
Papillary thyroid cancer (PTC) incidence has increased due to enhanced diagnostic imaging, leading to potential overlap with PA.
-
3
A study found a 29.2% prevalence of PA in patients with PTC and hypertension, compared to 20.4% in hypertensive controls, though not statistically significant.
-
4
Aldosterone may influence thyroid cancer biology through the mineralocorticoid receptor, highlighting its role in thyroid physiology.
-
5
Further research is needed to clarify the association between PA and PTC, particularly regarding hypertension screening in PTC patients.
